Marissa V.

BMS is poised to enter the Eosinophilic Esophagitis (EoE) market. Buried in the BMS Q2 2024 earnings call was news that company's eosinophilic esophagitis (EoE) treatment, cendakimab, successfully met Phase 3 clinical endpoints. Similar to already-approved, Dupixent, cendakimab is a biologic with subcutaneous injections every other week. Specifics on the data have yet to be released, this new agent could pose some competitive pressure for Dupixent in EoE. #gastroenterology #clinicaldata https://lnkd.in/g_2a2MWv

9

In the rare disease space, every launch decision counts. Transform complexity into a strategy to navigate expedited pathways, manage risk, and avoid launch delays. Hear from our experts Kapil Raina, Brian Williams, and Chris Zealey: https://lnkd.in/eYHYwDS5 #MarketAccess #MedicalAffairs #LaunchExcellence #AskHerspiegel

4

In the rare disease space, every launch decision counts. Transform complexity into a strategy to navigate expedited pathways, manage risk, and avoid launch delays. Hear from our experts Dr. Kapil Raina, Brian Williams, and Chris Zealey: https://lnkd.in/eYHYwDS5 #MarketAccess #MedicalAffairs #LaunchExcellence #AskHerspiegel

1

Our latest Perceptions and Insights Study revealed diversity gaps in clinical research. Read our article to learn what opportunities can improve clinical trial recruitment and participation, particularly among underrepresented populations. Read here: https://lnkd.in/dkH7RxXQ

1

Discover the latest enhancements to Labcorp Global Trial Connect, designed to streamline site workflows and boost clinical trial efficiency. These updates, driven by insights from collaboration with sponsors and sites, aim to empower investigator sites to focus more on what truly matters, patient care. Your commitment to patient care is why we’re committed to redefining clinical trial delivery. Learn more: https://lnkd.in/eavYncMz #ClinicalTrials #GlobalTrialConnect

9

Check out AscellaHealth’s Q2 Specialty & Rare Pipeline Digest featuring the latest updates on recent specialty drug approvals, upcoming reviews, CGT and biosimilar pipelines. If you haven’t already, make sure to subscribe today: https://lnkd.in/epMupw4w #specialtypharmacy #pharmaceuticals #raredisease #FollowAscellaHealth 

2

🔬 Outcomes4me partners with Labcorp to present a study at the 2024 San Antonio Breast Cancer Symposium, highlighting how digital education boosts HER2-low awareness among metastatic breast cancer patients. 🔄 Labcorp announces CFO Glenn Eisenberg's retirement, with Julia Wang set to take over the role from December 2, 2024. 💰 Labcorp reveals Q3 2024 results and updates full-year guidance. Key figures include $3.28 billion in revenue and $162 million in free cash flow. 🤝 Labcorp & NowDiagnostics team up to provide the only FDA-authorized over-the-counter syphilis test, expanding its accessibility in the U.S. 🩺 Labcorp boosts its STI testing capability with the addition of the First to Know® Syphilis Test, the first OTC blood test with FDA approval. #DataPorium #Labcorp #BreastCancerAwareness #HealthcareInnovation #CFOTransition At DataPorium, we track the financial performance, product sales, market share, and social network analysis. We also track the trends of nearly 1,000 products every quarter. 🚀 Want to see more? Head over to https://lnkd.in/duDAwekv and explore! 🔗 Visit our LinkedIn page https://lnkd.in/gJ2iKqKw today for exclusive updates—completely free!

1

That’s a wrap on American Society of Clinical Oncology (ASCO) 2024!   Looking for a quick recap? Check out our latest blog “Top News from Biggest Players at ASCO 2024” to see a summary of key data and takeaways.   https://lnkd.in/eFZm_kjy   #ASCO24 #Oncology #AdelphiResearch #MarketResearch

65

Good Morning from New Jersey! It's Day One at the Nexus Conference - 21st BioPharma Clinical Trials! What a fantastic opportunity to connect with leaders and innovators in the world of clinical trials. Today, we are excited to participate in the Panel Discussion on Running Clinical Trials in Different Geographic Regions: Assessing Opportunities and Challenges, featuring Rui Rui Zhang Xiang Business Director. Stay tuned for insights and key takeaways on overcoming the complexities of global trials! #ClinicalTrials #Biopharma #PharmaInnovation

64

1 Comment

Innovation starts here. For sponsors looking to make a real impact, #GeneTherapies are promising. Pharmacokinetic analysis can shape dosing strategies and provide input into drug safety & efficacy – learn more: https://bit.ly/3zDqPRs #CGT #GeneTherapy #PKassessments

17

In an article with Drug Target Review, Rebecca Goldstein, PhD, CMPP, Senior Principal, Strategic Consulting, explores how anchoring drug development programs to patient experiences can help navigate the evolving oncology landscape. Discover how patient-centered approaches are reshaping the landscape and the role of regulatory bodies like the FDA and EMA in integrating patient input through patient-reported outcomes and real-world evidence initiatives. Read the full article here. 👉🔗 https://lnkd.in/gUkjJrkR. #Oncology #DrugDevelopment #HealthcareInnovation

6

What’s behind the recent push to increase mandated coverage for biomarker testing? Attorney Bob Hearn discusses the factors driving legislative action toward payer coverage and the scope of various state laws, in a Q&A for the Laboratory Economics Compliance & Policy Report. Catch the full discussion here: https://bit.ly/3LaOzmb #HealthCare #BiomarkerTesting #HealthInsurance

9

The clinical research landscape is shifting, with larger site networks dominating through mergers and acquisitions. But there’s a unique advantage to diversifying with independent research sites. From navigating complex studies to overcoming recruitment challenges, see why independent sites should be part of your research strategy --> https://hubs.ly/Q02X9xtT0 hashtag #clinicalresearch hashtag #researchsites hashtag #patientrecruitment hashtag #complextrials

1

1 Comment

💡 Join WEP Clinical for an upcoming webinar to explore the challenges small and mid-sized biotech and pharma companies face in navigating clinical trials for advanced therapies like cell and gene therapies. These trials demand more than technical expertise—they require strategic partnerships and resource management. The featured speakers will discuss regulatory complexities, patient recruitment, logistical hurdles, and how partnering with specialized service providers can optimize trial design, streamline operations, and reduce risks. ➡️ Learn more + register here: https://buff.ly/3MIXuMq #Pharmaceutical #DrugDevelopment #PrecisionMedicine #ClinicalResearch #Biopharma #Biotech #CRO #PatientRecruitment #Regulatory #TherapeuticAreas #Pharma #CellAndGeneTherapy #CellAndGeneTherapies #CGT

52

Join HealthVerity and Quest on June 12 at 12:00 p.m. ET as we explore the breadth and scope of biomarker data readily available in HealthVerity Marketplace and discuss the variety of use cases for this powerful data type, including physician alerts to optimize provider education and outreach https://hubs.ly/Q02zlXGq0

4

🎧 Alicia Silver (Gedan), director of market access, cell and gene therapy at ADVI Health, was featured on the Prescription for Better Access podcast earlier this month to share insight on the current landscape and patient access challenges in #cellandgene therapy. Alongside Passage Health Associates' Eric Faulkner and co-hosts Mark Hansan (He/Him) and Scott Howell, Alicia expands on the reimbursement, coverage, and advancements of these life-changing therapies. Hear more of Alicia's insights: https://lnkd.in/eTkPS4Q9

15

What an informative read on the impact that site selection and support can have on radiopharmaceutical trials! Check out Sue Batchelor's BioPharma Dive article today, or stop by Booth 411 at #ESMO24 to speak with her about her insights: https://bit.ly/3XVxEv1

2

The US FDA recently released a diversity-focused draft guidance entitled "Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies." https://ow.ly/53mU50SNn62 Lya Rebelo, Commercial Enablement Manager at Citeline, discusses the future impact of this long-awaited guidance, how it differs from previous FDA diversity guidance, and what Norstella is doing as a life sciences partner to facilitate more diverse clinical development. Click the link in this post to read the full article.

32

Citeline's Lya Rebelo will be part of a roundtable discussion on the FDA's revised guidance for diversity in clinical trials and how it will impact both sponsors and sites. Register now: https://ow.ly/jcRi50SVWj3. #FDA #DiversityActionPlans #ClinicalTrialDiversity #DiversityInResearch #FDARegulations #InclusiveTrials #ClinicalTrialInclusion

5